^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    BCMA-targeted antibody-drug conjugate

    Related drugs:
    6d
    COSTA: A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma (clinicaltrials.gov)
    P2, N=33, Not yet recruiting, Cristiana Costa Chase, DO | Trial completion date: Oct 2027 --> Jun 2028 | Trial primary completion date: Oct 2025 --> May 2028
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Blenrep (belantamab mafodotin-blmf)
    6d
    Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant (clinicaltrials.gov)
    P2, N=4, Active, not recruiting, Roswell Park Cancer Institute | Suspended --> Active, not recruiting | N=20 --> 4
    Enrollment closed • Enrollment change • Minimal residual disease
    |
    lenalidomide • Blenrep (belantamab mafodotin-blmf)
    8d
    Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=62, Recruiting, Mayo Clinic | Trial completion date: May 2027 --> Jun 2034 | Trial primary completion date: May 2026 --> Jun 2029
    Trial completion date • Trial primary completion date
    |
    Blenrep (belantamab mafodotin-blmf)
    21d
    GEM-BELA-VRd: Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, PETHEMA Foundation | Trial completion date: Dec 2025 --> Jun 2026
    Trial completion date
    |
    lenalidomide • bortezomib • melphalan • Blenrep (belantamab mafodotin-blmf)
    28d
    ISABELA: Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=50, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting | Trial completion date: Dec 2026 --> Dec 2030 | Trial primary completion date: Dec 2025 --> Dec 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    pomalidomide • Sarclisa (isatuximab-irfc) • Blenrep (belantamab mafodotin-blmf)
    1m
    DREAMM-10: A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) (clinicaltrials.gov)
    P3, N=520, Recruiting, GlaxoSmithKline | Trial completion date: Apr 2032 --> Mar 2031 | Trial primary completion date: Dec 2030 --> Mar 2031
    Trial completion date • Trial primary completion date
    |
    lenalidomide • Darzalex (daratumumab) • Blenrep (belantamab mafodotin-blmf)
    2ms
    PrE1005: Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P3, N=500, Not yet recruiting, PrECOG, LLC.
    New P3 trial
    |
    lenalidomide • bortezomib • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Blenrep (belantamab mafodotin-blmf)
    2ms
    ALANIS: A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, GlaxoSmithKline | Trial completion date: Oct 2031 --> Feb 2032 | Initiation date: Dec 2025 --> Mar 2026 | Trial primary completion date: Apr 2027 --> Aug 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    bortezomib • cyclophosphamide • Blenrep (belantamab mafodotin-blmf)
    2ms
    Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma (clinicaltrials.gov)
    P2, N=41, Active, not recruiting, University of Pennsylvania | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    melphalan • Blenrep (belantamab mafodotin-blmf)
    2ms
    DREAMM 13: A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function (clinicaltrials.gov)
    P1, N=0, Withdrawn, GlaxoSmithKline | N=28 --> 0 | Recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    Blenrep (belantamab mafodotin-blmf)
    3ms
    GEM-BELA-VRd: Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, PETHEMA Foundation | Recruiting --> Active, not recruiting | Trial completion date: Jul 2025 --> Dec 2025
    Enrollment closed • Trial completion date
    |
    lenalidomide • bortezomib • melphalan • Blenrep (belantamab mafodotin-blmf)
    3ms
    Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant (clinicaltrials.gov)
    P2, N=20, Suspended, Roswell Park Cancer Institute | Recruiting --> Suspended
    Trial suspension • Minimal residual disease
    |
    lenalidomide • Blenrep (belantamab mafodotin-blmf)